ASX:CUVBiotechs
Clinuvel Pharmaceuticals H1 2026 Margin Compression Challenges Bullish Growth Narratives
Clinuvel Pharmaceuticals (ASX:CUV) has put out its H1 2026 scorecard with investors looking closely at the recent revenue and EPS trends relative to its trailing performance. The company has seen total revenue move from A$55.4 million in H2 2024 to A$59.4 million in H2 2025, while basic EPS shifted from A$0.49 to A$0.44 over the same halves. This sets the backdrop for trailing 12 month figures that include revenue of A$96.9 million and basic EPS of A$0.65. With trailing net profit margins...